METHODS: An economic model was developed to compare treatment costs of 2 L interventions depending on the treatment duration. Treatment duration was measured by progression-free survival (PFS), identified based on a systematic review. Total and average costs were calculated over 5 years to evaluate incremental costs at median PFS for each intervention.
RESULTS: Average costs per month at median PFS ranged from €2846 (95% CI: 5067-1641) to €40 535 (95% CI: 91180-N/A) for BR and liso-cel, respectively. Incremental costs at the lowest median PFS (R-GemOx: 5.3 months) revealed -€664, €5560, €11 817, €53 145, and €67 745 for BR, Tafa-L, pola-BR, axi-cel, and liso-cel as compared to R-GemOx, respectively.
CONCLUSIONS: Analyses uncovered a variation of incremental costs of 2 L transplant-ineligible DLBCL interventions as a function of time leading to amortization of high-priced interventions.
方法:开发了一种经济模型,以根据治疗持续时间比较2L干预措施的治疗费用。治疗持续时间通过无进展生存期(PFS)来衡量,根据系统审查确定。计算了5年内的总成本和平均成本,以评估每个干预措施在平均PFS时的增量成本。
结果:BR和Liso-cel的平均PFS每月平均成本为2846欧元(95%CI:5067-1641)至40535欧元(95%CI:91180-N/A),分别。最低平均PFS(R-GemOx:5.3个月)的增量成本显示-BR664欧元,5560欧元,11817欧元,53145欧元和67745欧元,Tafa-L,pola-BR,axi-cel,与R-GemOx相比,分别。
结论:分析揭示了2L移植不合格的DLBCL干预措施的增量成本随时间的变化,导致高价干预措施的摊销。